Neuronetics Q3 revenue $17.9M (+8% YoY); net loss $(9.4)M; narrows FY 2023 guidance

Neuronetics, Inc.

2023-Q3 EPS reported -$0.87 revenue$51,034,000

Revenue $17.9M (+8% YoY); record US treatment session revenue $13.1M (+10% YoY).
Gross margin 65.8% (down from 78.4%) due to $1.9M inventory write-off; adjusted 77.3%.
Net loss $(9.4)M or $(0.33)/share vs $(7.6)M or $(0.28)/share last year.
Drew down remaining $22.5M from SLR credit facility; cash $35.8M vs $70.3M at Dec 31, 2022.
FY 2023 revenue guidance narrowed to $70-72M; Q4 revenue expected $19-21M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Neuronetics, Inc. reported the three months ended September 30, 2023 results: revenue $17.9 million, net income $(9.4) million, EPS $(0.33) per share.

Period: the three months ended September 30, 2023
Revenue: $17.9 million
Net income: $(9.4) million
EPS: $(0.33) per share
Result: reported results

Exact text from the filing

therapies in the world, today announced its financial and operating results for the third quarter of 2023. Third Quarter 2023 Highlights ● Third quarter 2023 revenue of $17.9 million, an increase of 8% over the third quarter of 2022 ● Record U.S. treatment session revenue of $13.1 million ● Shipped 43 NeuroStar systems Recent Operational Highlights ●

View on SEC.gov

Browse all earnings releases →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.